Encapsulife & It's 20 Years of Research Progress

Critical Path Approach

Instead of development funding through venture capital, Encapsulife has taken a critical path for its research, based on peer-reviewed basic science. Funding for this approach was primarily from the Juvenile Diabetes Research Foundation (JDRF), NASA, The Evans-Gilruth Foundation Ronald McDonald Children's Charities, other non-profit sources and private investments.

Encapsulife's management has engaged in numerous collaborations with U.S. and international researchers, but the primary locus for Dr. Wang's research and experiments has been The Vanderbilt University Center for Micro-Gravity Research and Applications. At Vanderbilt, Dr. Wang, a physicist, has organized and managed an interdisciplinary engineering and medical research team that includes senior researchers from the Vanderbilt University community.

A Long History of New Technology

Encapsulife, Inc. is a private corporation with a substantial patent portfolio, processes, and products that are derivative of micro-gravity research  first conducted during a 1985 NASA Shuttle mission by astronaut-scientist, Dr. Taylor Wang. Dr. Wang is Encapsulife's Founder, Chairman and CEO.

Encapsulife is developing new nano-technologies in the bio-medical field to provide a "living cell/functional cure" for diabetes. On February 15, 2008, Encapsulife published peer-reviewed research that marks it's global leadership in developing a practical "immunoisolation" system to encapsulate transplanted pancreatic Beta cells and enable these islet cells to survive and efficiently deliver insulin in a diabetic host  without immunosuppression drugs and their negative side-effects. This process reverses diabetes by allowing insulin to be delivered in a manner functionally identical to that of non-diabetics.

Success in achieving a living-cell/functional cure for diabetes will constitute a historic medical breakthrough  with the potential to scale treatments to 180 million diabetics worldwide.

Encapsulife nano-technologies and therapeutic strategies to reverse diabetes also have applications to address numerous other medical conditions and other hormone-deficient diseases, such as liver disease, Huntington's Disease, hemophilia, and neurological disorders, including Alzheimer's.

Encapsulife, Inc. is a private corporation that is putting its substantial patent portfolio, processes, and products  derived from micro-gravity research  to work in the development of new nano-technologies in the bio-medical field to provide a "living cell/functional cure" for diabetes and other diseases.